Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.

Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, Zhao B.

Sci Rep. 2016 Sep 20;6:33860. doi: 10.1038/srep33860. Erratum in: Sci Rep. 2017 Feb 17;7:41197.


Radiomic phenotype features predict pathological response in non-small cell lung cancer.

Coroller TP, Agrawal V, Narayan V, Hou Y, Grossmann P, Lee SW, Mak RH, Aerts HJ.

Radiother Oncol. 2016 Jun;119(3):480-6. doi: 10.1016/j.radonc.2016.04.004. Epub 2016 Apr 13.


Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.

Yip SS, Kim J, Coroller TP, Parmar C, Velazquez ER, Huynh E, Mak RH, Aerts HJ.

J Nucl Med. 2017 Apr;58(4):569-576. doi: 10.2967/jnumed.116.181826. Epub 2016 Sep 29.


Radiomic-Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLC.

Coroller TP, Agrawal V, Huynh E, Narayan V, Lee SW, Mak RH, Aerts HJWL.

J Thorac Oncol. 2017 Mar;12(3):467-476. doi: 10.1016/j.jtho.2016.11.2226. Epub 2016 Nov 27.


[Application of radiomics captured from CT to predict the EGFR mutation status and TKIs therapeutic sensitivity of advanced lung adenocarcinoma].

Yang CS, Chen WD, Gong GZ, Li ZJ, Qiu QT, Yin Y.

Zhonghua Zhong Liu Za Zhi. 2019 Apr 23;41(4):282-287. doi: 10.3760/cma.j.issn.0253-3766.2019.04.007. Chinese.


Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?

Digumarthy SR, Padole AM, Gullo RL, Sequist LV, Kalra MK.

Medicine (Baltimore). 2019 Jan;98(1):e13963. doi: 10.1097/MD.0000000000013963.


Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.


Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.

Giuliani J, Martelli S, Remo A, Bonetti A.

Tumori. 2015 Jul 24;101(4):e115-7. doi: 10.5301/tj.5000317.


Associations of Radiomic Data Extracted from Static and Respiratory-Gated CT Scans with Disease Recurrence in Lung Cancer Patients Treated with SBRT.

Huynh E, Coroller TP, Narayan V, Agrawal V, Romano J, Franco I, Parmar C, Hou Y, Mak RH, Aerts HJ.

PLoS One. 2017 Jan 3;12(1):e0169172. doi: 10.1371/journal.pone.0169172. eCollection 2017.


Impact of experimental design on PET radiomics in predicting somatic mutation status.

Yip SSF, Parmar C, Kim J, Huynh E, Mak RH, Aerts HJWL.

Eur J Radiol. 2017 Dec;97:8-15. doi: 10.1016/j.ejrad.2017.10.009. Epub 2017 Oct 9.


3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.

Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S.

J Nucl Med. 2012 Mar;53(3):443-50. doi: 10.2967/jnumed.111.096503. Epub 2012 Feb 13.


The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.

Kim H, Park CM, Keam B, Park SJ, Kim M, Kim TM, Kim DW, Heo DS, Goo JM.

PLoS One. 2017 Nov 3;12(11):e0187500. doi: 10.1371/journal.pone.0187500. eCollection 2017.


Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer.

Lara-Guerra H, Chung CT, Schwock J, Pintilie M, Hwang DM, Leighl NB, Waddell TK, Tsao MS.

Lung Cancer. 2012 May;76(2):235-41. doi: 10.1016/j.lungcan.2011.10.020. Epub 2011 Nov 22.


(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.

van Gool MH, Aukema TS, Schaake EE, Rijna H, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers SA, van Tinteren H, Klomp HM.

Ann Surg Oncol. 2014 Sep;21(9):2831-7. doi: 10.1245/s10434-014-3791-6. Epub 2014 May 21.


Non-invasive classification of non-small cell lung cancer: a comparison between random forest models utilising radiomic and semantic features.

Bashir U, Kawa B, Siddique M, Mak SM, Nair A, Mclean E, Bille A, Goh V, Cook G.

Br J Radiol. 2019 Jul;92(1099):20190159. doi: 10.1259/bjr.20190159. Epub 2019 Jun 5.


Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.

Keam B, Lee SJ, Kim TM, Paeng JC, Lee SH, Kim DW, Jeon YK, Chung DH, Kang KW, Chung JK, Heo DS.

J Thorac Oncol. 2015 Aug;10(8):1189-94. doi: 10.1097/JTO.0000000000000569.


Stability of radiomic features in CT perfusion maps.

Bogowicz M, Riesterer O, Bundschuh RA, Veit-Haibach P, Hüllner M, Studer G, Stieb S, Glatz S, Pruschy M, Guckenberger M, Tanadini-Lang S.

Phys Med Biol. 2016 Dec 21;61(24):8736-8749. Epub 2016 Nov 28.


Feature selection methodology for longitudinal cone-beam CT radiomics.

van Timmeren JE, Leijenaar RTH, van Elmpt W, Reymen B, Lambin P.

Acta Oncol. 2017 Nov;56(11):1537-1543. doi: 10.1080/0284186X.2017.1350285. Epub 2017 Aug 22.


Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.

Li N, Ou W, Ye X, Sun HB, Zhang L, Fang Q, Zhang SL, Wang BX, Wang SY.

Ann Surg Oncol. 2014 Jun;21(6):2091-6. doi: 10.1245/s10434-014-3586-9. Epub 2014 Mar 1.


Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study.

Chang JW, Hou MM, Hsieh JJ, Cheung YC, Wang HM, Chen JS, Wang CH, Chen CH, Yeh KY, Ou LY, Hsieh CH, Wu HD, Chen YT, Chang IC, Huang SF.

Biomed J. 2015 May-Jun;38(3):221-8. doi: 10.4103/2319-4170.138320.

Supplemental Content

Support Center